Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Buenos Aires Breast Cancer Symposium 2024: bridging basic and clinical research in breast cancer.
Abba M, Behbod F, Ceppi P, Chammas R, Clarke R, Dalotto T, De Siervi A, Gómez Abuin G, Gottifredi V, Hoadley KA, Jerry J, Juric D, Kordon E, Lanari C, Lee A, Mahmoud YD, Mandó P, Maurer J, Mauro F, Miller T, Muller WJ, Novaro V, Oesterreich S, Park C, Pettit S, Razavi P, Richer J, Roqué M, Rossi M, Salaberry PJ, Salatino M, Sciacca M, Vallone SA, Vilarullo RN, Vivanco M, Waisberg F, Welm A, Wolos VJ. Abba M, et al. Among authors: juric d. Medicina (B Aires). 2025;85(3):586-596. Medicina (B Aires). 2025. PMID: 40577145 Free article. English.
Emergence of Multidrug-Resistant Campylobacter jejuni in a Common Variable Immunodeficiency Patient: Evolution of Resistance Under the Selective Antibiotic Pressure.
Juzbašić T, Andrijašević N, Ferenčak I, Jurić D, Šoprek S, Poje Janeš V, Žmak L, Tambić Andrašević A, Gverić Grginić A. Juzbašić T, et al. Among authors: juric d. Trop Med Infect Dis. 2025 Jun 12;10(6):165. doi: 10.3390/tropicalmed10060165. Trop Med Infect Dis. 2025. PMID: 40559732 Free PMC article.
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
Gambardella V, Accordino MK, Bedard PL, Cervantes A, Hamilton E, Italiano A, Kalinsky K, Krop IE, Oliveira M, Saura C, Schmid P, Turner NC, Varga A, Fernandez-Saranillo A, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman JL, Juric D, Jhaveri KL. Gambardella V, et al. Among authors: juric d. ESMO Open. 2025 Jun 12;10(7):105303. doi: 10.1016/j.esmoop.2025.105303. Online ahead of print. ESMO Open. 2025. PMID: 40513140 Free article.
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.
Jhaveri KL, Im SA, Saura C, Loibl S, Kalinsky K, Schmid P, Loi S, Thanopoulou E, Shankar N, Jin Y, Stout TJ, Clark TD, Song C, Juric D, Turner NC. Jhaveri KL, et al. Among authors: juric d. N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2501796. Online ahead of print. N Engl J Med. 2025. PMID: 40454641
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.
Varkaris A, Wang K, Nouri M, Kozlova N, Schmidt DR, Stavridi A, Arai S, Ambrosio N, Poluben L, Jimenez-Vacas JM, Westaby D, Carmichael J, Xie F, Figueiredo I, Buroni L, Neeb A, Gurel B, Chevalier N, Brown L, Voznesensky O, Chen SY, Russo JW, Yuan X, Juric D, Beltran H, De Bono JS, Vander Heiden MG, Einstein DJ, Muranen T, Corey E, Sharp A, Balk SP. Varkaris A, et al. Among authors: juric d. Nat Commun. 2025 May 28;16(1):4931. doi: 10.1038/s41467-025-60238-x. Nat Commun. 2025. PMID: 40436896 Free PMC article.
Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets.
Vijay V, Karisani N, Shi L, Hung YH, Vu P, Kattel P, Kenney L, Merritt J, Adil R, Wu Q, Zhen Y, Morris R, Kreuzer J, Kathiresan M, Herrera Lopez XI, Ellis H, Gritti I, Lecorgne L, Farag I, Popa A, Shen W, Kato H, Xu Q, Balasooriya ER, Wu MJ, Wan J, Kondo H, Chaturantabut S, Raghavan S, Hall MD, Patnaik S, Shen M, Kelley RK, Cleary JM, Lawrence MS, Root DE, Patra KC, Silveira VS, Benes CH, Deshpande V, Juric D, Sellers WR, Ferrone CR, Haas W, Vazquez F, Getz G, Bardeesy N. Vijay V, et al. Among authors: juric d. Cancer Discov. 2025 May 12. doi: 10.1158/2159-8290.CD-24-1383. Online ahead of print. Cancer Discov. 2025. PMID: 40353839
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
Bedard PL, Jhaveri KL, Accordino MK, Cervantes PA, Gambardella V, Hamilton E, Italiano PA, Kalinsky PK, Krop PIE, Oliveira M, Schmid PP, Saura C, Turner PN, Varga A, Cheeti S, Dey A, Hilz S, Hutchinson KE, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman JL, Aimi J, Song K, Juric D. Bedard PL, et al. Among authors: juric d. Eur J Cancer. 2025 May 15;221:115397. doi: 10.1016/j.ejca.2025.115397. Epub 2025 Mar 30. Eur J Cancer. 2025. PMID: 40203765 Clinical Trial.
[Osteochondral lesions of the talus].
Juric D, Krähenbühl N. Juric D, et al. Ther Umsch. 2024 Dec;81(7):254-257. doi: 10.23785/TU.2024.07.005. Ther Umsch. 2024. PMID: 40079715 Review. German.
197 results